Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
90 participants
INTERVENTIONAL
2013-03-31
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Prevention of Pain Associated With Rocuronium Injection
NCT02524743
Rocuronium Dose Finding Study After Single-shot or Steady-state Propofol Anesthesia
NCT02054468
Lidocaine, Paracetamol, and Dexmedetomidine for Rocuronium Injection Pain
NCT07169227
Comparison of a Pain Pump Versus Injectable Medication for Analgesia in Knee Arthroscopy
NCT01242644
Pain on Injection of Propofol: a Comparison of Lidocaine and Alkalinized Lidocaine
NCT01773044
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
brevibloc (esmolol)
Group E will receive esmolol (1 mg/kg), Group L lidocaine (0.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL)
Esmolol
Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
rocuronium
0.05 mg/kg rocuronium
Aritmal (Lidocaine)
Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
Lidocaine
Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).
rocuronium
0.05 mg/kg rocuronium
Placebo (NaCl 0.9%, 5 ml)
Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
rocuronium
0.05 mg/kg rocuronium
Placebo
Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lidocaine
Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).
Esmolol
Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
rocuronium
0.05 mg/kg rocuronium
Placebo
Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Undergoing general anesthesia for elective surgery
Exclusion Criteria
* Chronic pain
* Pregnancy
* Withdrawal of consent by the patient
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ankara Diskapi Training and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fatma Kavak Akelma
Specialist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fakelma 05327079113
Role: PRINCIPAL_INVESTIGATOR
Diskapi Teaching and Research Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Diskapi Teaching and Research Hospital
Ankara, Altindag, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ESM 0538
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.